Equities

Proteome Sciences PLC

PRM:LSE

Proteome Sciences PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1.77
  • Today's Change0.015 / 0.85%
  • Shares traded504.75k
  • 1 Year change-58.25%
  • Beta0.7887
Data delayed at least 20 minutes, as of Feb 06 2026 16:29 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Proteome Sciences PLC's net income fell 39.38% from a loss of 2.44m to a larger loss of 3.41m despite relatively flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 67.24% to 86.29%.
Gross margin17.43%
Net profit margin-73.60%
Operating margin-50.12%
Return on assets-37.44%
Return on equity--
Return on investment--
More ▼

Cash flow in GBPView more

In 2024, cash reserves at Proteome Sciences PLC fell by 899.00k. Cash Flow from Financing totalled 151.00k or 3.09% of revenues. In addition the company used 826.00k for operations while cash used for investing totalled 224.00k.
Cash flow per share-0.0085
Price/Cash flow per share--
Book value per share-0.0291
Tangible book value per share-0.0434
More ▼

Balance sheet in GBPView more

Proteome Sciences PLC appears to have a weak balance sheet, highlighted by its negative owner's equity. Additionally, this company's debt load is greater than its assets while day-to-day operations are losing money.
Current ratio0.1088
Quick ratio0.0774
Total debt/total equity--
Total debt/total capital2.26
More ▼

Growth rates in GBP

Year on year, growth in earnings per share excluding extraordinary items dropped -39.37%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		18.31
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.